Home › Prostate Cancer › NCT06824818
Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
A Feasibility Trial of LHRH Agonist Discontinuation in Elderly Prostate Cancer Patients
Who can join
Ages 70 and older · Men
Full eligibility criteria
Inclusion Criteria: * Prostate cancer with \>3 years of LHRH agonist therapy. * Age ≥70 years. * ECOG performance status ≤2 * Baseline testosterone of \< 20 ng/ml * No prior chemotherapy or Lu-PSMA (unless survival predictions are favorable). * Ability to understand and sign informed consent. Exclusion Criteria: * none
About the study
This study seeks to identify if it is feasible to stop Luteinizing Hormone-Releasing Hormone (LHRH) Agonist Therapy in elderly men with prostate cancer. We hypothesize that elderly prostate cancer patients on long term androgen ablation with LHRH agonists will be permanently castrated and do not require ongoing LHRH agonist therapy. Participants will be monitored by testosterone testing throughout study.
What is being tested
- LHRH Agonist Therapy Discontinuation (behavioral)
Sponsor: University of Chicago · Participants: 155 · Started: 2026-06
Contact the study team
- Clinical Trials Intake · Phone: 1-855-702-8222
Official record on ClinicalTrials.gov — NCT06824818
Locations in the U.S.
| Illinois | The University of Illinois at Chicago (UIC), Chicago UChicago Medicine Comprehensive Cancer Center, Chicago (Not yet recruiting) |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.